Inflammatory markers at baseline correlate with subsequent clinical response to quetiapine in patients with bipolar disorder.

IF 1.7

Human psychopharmacology Pub Date : 2022-11-01 Epub Date: 2022-09-07 DOI:10.1002/hup.2854

Marco Ferrari, Marco Godio, Stefano Martini, Camilla Callegari, Marco Cosentino, Franca Marino

{"title":"Inflammatory markers at baseline correlate with subsequent clinical response to quetiapine in patients with bipolar disorder.","authors":"Marco Ferrari, Marco Godio, Stefano Martini, Camilla Callegari, Marco Cosentino, Franca Marino","doi":"10.1002/hup.2854","DOIUrl":null,"url":null,"abstract":"Objectives: Recent studies proposed the existence of a correlation between patients' inflammatory status and therapy response in bipolar disorder (BD). Here we investigated the correlation between levels of inflammatory markers and quetiapine (QUE) effects in BD patients.Methods: In 15 hospitalised BD patients, we investigated changes in inflammatory markers such as C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR) and cytokines after a 6-week treatment with QUE monotherapy.Results: We found QUE treatment to significantly reduce CRP and IL-6 plasma levels. Moreover, we found higher CRP and IL-6 plasma levels at baseline correlated with better improvement of patients' clinical symptoms.Conclusion: The reported results, although preliminary, could be useful in clinical practice, providing not only markers for QUE response, but also allowing for identification of new targets and new therapies for the treatment of this condition.","PeriodicalId":520641,"journal":{"name":"Human psychopharmacology","volume":" ","pages":"e2854"},"PeriodicalIF":1.7000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/hup.2854","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/9/7 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 4

Abstract

Objectives: Recent studies proposed the existence of a correlation between patients' inflammatory status and therapy response in bipolar disorder (BD). Here we investigated the correlation between levels of inflammatory markers and quetiapine (QUE) effects in BD patients.

Methods: In 15 hospitalised BD patients, we investigated changes in inflammatory markers such as C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR) and cytokines after a 6-week treatment with QUE monotherapy.

Results: We found QUE treatment to significantly reduce CRP and IL-6 plasma levels. Moreover, we found higher CRP and IL-6 plasma levels at baseline correlated with better improvement of patients' clinical symptoms.

Conclusion: The reported results, although preliminary, could be useful in clinical practice, providing not only markers for QUE response, but also allowing for identification of new targets and new therapies for the treatment of this condition.

查看原文本刊更多论文

基线炎症标志物与双相情感障碍患者随后对喹硫平的临床反应相关。

目的:最近的研究表明，双相情感障碍(BD)患者的炎症状态与治疗反应之间存在相关性。在这里，我们研究了炎症标志物水平与BD患者喹硫平(QUE)效应之间的相关性。方法:在15例住院BD患者中，我们研究了炎症标志物如c反应蛋白(CRP)、红细胞沉降率(ESR)和细胞因子在接受QUE单药治疗6周后的变化。结果:我们发现QUE治疗可显著降低CRP和IL-6血浆水平。此外，我们发现基线时较高的CRP和IL-6血浆水平与患者临床症状的改善相关。结论:报告的结果虽然是初步的，但在临床实践中可能是有用的，不仅提供了QUE反应的标志物，而且还允许确定治疗该疾病的新靶点和新疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Human psychopharmacology

自引率

0.00%

发文量